Table 2.
Overview of patient’s data
| Parameter | Number (%) |
|---|---|
| Patients, total | 36 |
| Age, years, median | 60 |
| Age, years, range | 44–76 |
| Sex, male | 20 (55.5%) |
| Sex, female | 16 (44.5%) |
| MM subtype | |
| IgG Kappa/Lambda | 12 (33.3%)/7 (19.4%) |
| IgA Kappa/Lambda | 3 (8.3%)/2 (5.6%) |
| IgM Lambda | 1 (2.8%) |
| Light chain only, Kappa | 5 (13.9%) |
| Light chain only, Lambda | 3 (8.3%) |
| Non-secretory | 3 (8.3%) |
| High-dose therapies with SCTs | |
| One autologous SCT | 17 (47.2%) |
| Two autologous SCT | 12 (33.3%) |
| Three autologous SCT | 1 (2.8%) |
| Allogeneic SCT (following autologous) | 6 (16.7%) [5(13.9%)] |
| Therapy lines before current progress | |
| First line | 13 (36.1%) |
| Second line | 9 (25%) |
| Third line | 8 (22.2%) |
| Fourth line | 4 (11.1%) |
| Fifth line | 2 (5.6%) |
| Median | 2 |
| ISS2 stage at current progress | |
| I | 19 (52.8%) |
| II | 13 (36.1%) |
| III | 4 (11.1%) |
| Cytogenetics on FISH | |
| High-eisk | 6 (16.6%) |
| Non-high-risk | 15 (41.7%) |
| Cytogenetics not available | 15 (41.7%) |
| LDH | |
| Elevated (> 250 U/l) | 20 (55.5%) |
| Normal (≤ 250 U/l) | 16 (44.5%) |
| Best response after last therapy line | |
| CR | 10 (27.7%) |
| vgPR | 5 (13.9%) |
| PR | 19 (52.8%) |
| SD | 2 (5.6%) |
SCT stem cell transplantation, ISS international staging system, FISH fluorescence in situ hybridization, CR complete remission, vgPR very good partial remission, PR partial remission, SD stable disease